Soleno Therapeutics, Inc.
SLNO
$48.12
-$0.91-1.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 102.16% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 102.16% | -- | |||
| Cost of Revenue | 63.94% | -- | |||
| Gross Profit | 102.99% | -- | |||
| SG&A Expenses | 19.53% | -3.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.70% | -10.98% | |||
| Operating Income | 518.86% | 87.32% | |||
| Income Before Tax | 652.53% | 89.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 652.53% | 89.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 652.53% | 89.24% | |||
| EBIT | 518.86% | 87.32% | |||
| EBITDA | 571.78% | 88.36% | |||
| EPS Basic | 622.83% | 90.16% | |||
| Normalized Basic EPS | 798.21% | 91.91% | |||
| EPS Diluted | 603.75% | 90.16% | |||
| Normalized Diluted EPS | 777.85% | 91.91% | |||
| Average Basic Shares Outstanding | 5.64% | 9.32% | |||
| Average Diluted Shares Outstanding | 8.79% | 9.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||